IN THE NEWS
Discover the latest insight in these articles featuring inThought analysts and executives:
The MM&M Podcast 2.5.2021: inThought Research’s Dr. Leon Henderson-MacLennan
Is biopharma slowly cracking the code on Alzheimer’s disease? Leon Henderson-MacLennan, M.D., of inThought Research, joins Marc Iskowitz, editor-at-large for MM+M, to explain why January was a pivotal month in neuroscience and why marketers should watch this space.
Pipeline Report 2021: Promising Drugs Tick Along Across a Range of Conditions
As drug developers swim hard and fast to neutralize COVID-19 with vaccines and therapeutics, they are also working to get other important drugs approved amid looming threats of halts and delays. 2021 is looking to be a big year for the pharma pipeline.
Biogen’s Touted Alzheimer’s Drug Receives Thumbs-Down from FDA Advisory Panel
Biogen’s quest to get a long-awaited new Alzheimer’s drug to market took yet another twist on Friday afternoon as the FDA advisory committee (AdCom) issued an unfavorable vote on recommending the drug for approval.
inDemic Announces New Research Tool for the COVID-19 Pandemic
inDemic announces the launch of its COVID-19 knowledge management system. inDemic’s initial focus is on COVID-19 therapies and vaccines. The site provides in-depth news and analysis of therapies that are being tested to treat COVID-19.
COVID-19 Therapeutics Expert Call
Bloomberg Intelligence and inThought will host a call with immunology experts to discuss development of a Covid-19 therapy and how best to interpret clinical data once they begin to emerge.
COVID-19 Vaccines Expert Call
Bloomberg Intelligence healthcare analysts and inThought Research experts share their views on the prospects for developing a vaccine against the novel coronavirus.
Pipeline Report 2020: Drugs Rising from R&D Purgatory
inThought Research president Ben Weintraub discusses drugs re-emerging from “R&D purgatory” with MM&M.
The MM&M Podcast 5.29.2019: inThought Research’s Michelle Rivera
inThought Research analyst Michelle Rivera speaks with MM&M about the pathophysiology of the disease spinal muscular atrophy (SMA), the SMA drug pipeline, and how payers may react expensive drugs.
Novartis gene therapy gets green light, and a price tag of $2.1 million
The 2019 pipeline report: Changing the treatment paradigm
Are today’s developmental drugs tomorrow’s blockbusters? MM&M surveys what’s ahead for top candidates in six therapeutic categories.
Promising rare conditions treatments could upend the market hierarchy
With less than 14% of Phase I to III drug candidates winning FDA approval, unforeseen roadblocks can derail even the most promising clinical research programs.
Orphan drugs leveraging new tech promise to cure disease
Did the market overreact to Biogen’s Alzheimer’s data?
The 2018 pipeline report: Aspiring assets to keep an eye on
The immuno-oncology market prepares for the inevitable question: ‘What’s next?’
